Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Sponsors and Collaborators

Eisai Inc.
Quintiles

Contact
Mark Shelton
Mark.Shelton@quintiles.com

Principal Investigator
Mark Shelton, Quintiles

ClinicalTrials.gov Identifier
NCT01126749

Loading links....
You must be a registered member of Renal and Urology News to post a comment.